DIRS.INFO The most relevant business & tech news

☆ Ozempic and Wegovy may help curb alcohol addiction, study suggests
▼ + stars: | 2024-11-13 | by ( Kaitlin Sullivan | Kaitlin Sullivan Is A Contributor For Nbcnews.Com Who Has Worked With Nbc News Investigations. She Reports On Health | Science | ) www.nbcnews.com time to read: +5 min

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests. Just over 28 million adults in the U.S. have alcohol addiction, according to the National Institute on Alcohol Abuse and Alcoholism. Several other studies have examined drinking habits among people taking GLP-1 drugs who do not have alcohol use disorder. Around 75,000 people in the study used some type of medication to treat alcohol use disorder. So far, the clearest results have come from studies on alcohol addiction — but there is still a lot to understand.

Persons: Ozempic, ”, Alex DiFeliceantonio, Markku, “, ” DiFeliceantonio, Christian Hendershot, Hendershot, Lähteenvuo, DiFeliceantonio, ” Hendershot Organizations: Psychiatry, National Institute, Alcohol, Biomedical Research Institute, Niuvanniemi Hospital, University of Southern California Institute for Addiction Science Locations: Sweden, U.S, Virginia, Finland, Swedish

☆ Semaglutide linked to reduced arthritis knee pain in people with obesity, study finds
▼ + stars: | 2024-10-30 | by ( Kaitlin Sullivan | Kaitlin Sullivan Is A Contributor For Nbcnews.Com Who Has Worked With Nbc News Investigations. She Reports On Health | Science | ) www.nbcnews.com time to read: +4 min

People who lost a significant amount of weight with semaglutide saw major improvements in osteoarthritis knee pain, research published Wednesday in the New England Journal of Medicine finds. “Any sort of dramatic weight loss will relieve pain,” Bliddal said. In another study led by Bliddal, people with knee osteoarthritis were given an older weight loss drug, liraglutide. The average BMI in that study was about 32, lower than the average in the new study. Most of the people in the study had a BMI over 35, and nearly half had a BMI of over 40.

Persons: semaglutide, Wegovy —, ”, Daniel Wiznia, Henning Bliddal, David Felson, That’s, ” Wiznia, ” Bliddal, Bliddal, liraglutide, Felson, Wiznia, “, ” Felson Organizations: New England, of Medicine, Novo Nordisk, Yale Medicine, University of Copenhagen, Boston University Chobanian, Avedisian School of Medicine, BMI, Food and Drug Administration Locations: Denmark

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia. Another study, published in August, found that semaglutide appeared to cut the risk of dementia in people with Type 2 diabetes. Type 2 diabetes is a risk factor for dementia and Alzheimer’s. The study found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The biggest difference was seen when comparing patients who took semaglutide to those who took insulin: Semaglutide patients had a 70% lower risk of Alzheimer’s, the study found.

Persons: —, semaglutide, ”, Stephen Salloway, ” Salloway, Rong Xu, liraglutide, Xu, ” Xu, they’re, Salloway, they’ve, Donna Wilcock, there’s, ” Wilcock, Dr, Alberto Espay, Espay, What’s, “, ” Espay Organizations: Alzheimer’s Association, Conference, Novo Nordisk, Warren Alpert Medical, Brown University, Center, Artificial Intelligence, Case Western Reserve University School of Medicine, Drug Administration, ”, Alzheimer’s, Indiana University School of Medicine, University of Cincinnati College of Medicine Locations: Novo, Rhode Island, Ohio

☆ Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
▼ + stars: | 2024-10-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Novo Nordisk 's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Alzheimer's disease is often diagnosed in the mild dementia stage, when a person has significant trouble with memory and thinking. But the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. by 2050. Novo Nordisk, which did not fund the new Case Western study, is also examining semaglutide in a late-stage study on Alzheimer's patients. In the liraglutide research, data from a midstage trial found that the drug may slow the progression of Alzheimer's disease by protecting patients' brains.

Persons: Semaglutide, Dr, Rong Xu, it's, Xu, Eli Lilly, Wegovy, Eli Lilly's Organizations: Novo Nordisk, Alzheimer's Association, Case Western Reserve University, CNBC, Nordisk, Case, National Institutes of Health, GLP Locations: U.S, Novo

☆ Beyond Novo: Fund manager likes this under-the-radar pharma stock with a weight loss drug in the works
▼ + stars: | 2024-10-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

"Maybe that weight loss product (by United Laboratories) works, maybe it doesn't. United Laboratories' price-to-earnings of 5.8 times is a fraction of the 34.3 times that Novo Nordisk is trading at, Peche added. [United Laboratories] is making smooth progress in R & D and targets to launch Liraglutide in 2024. Their comments follow United Laboratories' "faster than expected earnings" growth in the first half of the year. Analysts' average price target on United Laboratories is 12.95 Hong Kong dollars, giving it 28.2% potential upside.

Persons: Sean Peche, it's, Peche, there's, that's, Eli Lilly, Amgen, Carol Dou, Sunny Chen, UOB Kay Hian, bode Organizations: Novo Nordisk, Ranmore Fund Management, United Laboratories, Pfizer, AstraZeneca, Global Equity Fund, Hong, Hong Kong bourse, HK Locations: Hong Kong, Novo, Europe, U.S

☆ Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
▼ + stars: | 2024-09-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Novo Nordisk 's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study released Wednesday. The active ingredient in Ozempic, semaglutide, was associated with a "significantly lower" opioid overdose risk than other diabetes medications in people diagnosed with both Type 2 diabetes and opioid use disorder, said the paper published in JAMA Network Open. Around 3,000 people were prescribed semaglutide injections, while the remaining patients received treatments that ranged from insulins to older GLP-1s for diabetes. That reflects a 58% lower risk of opioid overdose in patients who took semaglutide, Xu said.

Persons: Dr, Rong Xu, Eli Lilly, Lilly's, Xu Organizations: Novo Nordisk, JAMA, Case Western Reserve University, Centers for Disease Control, National Center for Drug, U.S, National Institutes of Health, Novo Nordisk's Victoza Locations: London, Britain, Novo

☆ The next big market for weight-loss drugs: children
▼ + stars: | 2024-09-11 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Novo Nordisk's American rival, Eli Lilly, has also been testing obesity-beating drugs for children as young as six. Wegovy and similar drugs for weight loss have become a huge business. The drugs' success has made Novo Nordisk the most valuable company in Europe. AdvertisementChildhood obesityAn FDA approval on weight loss drugs for children could open up a new market for Novo Nordisk. In June, US Sen. Bernie Sanders announced that Novo Nordisk CEO Lars Jørgensen would testify before the committee on September 24 at a hearing focusing on the prices that Novo Nordisk charges Americans for their drugs, Ozempic and Wegovy.

Persons: —, Saxenda, Novo, Claudia Fox, Eli Lilly, Goldman Sachs, Wegovy, Sen, Bernie Sanders, Lars Jørgensen, Sanders Organizations: Service, BMI, Business, FDA, Financial Times, Novo Nordisk, Centers for Disease Locations: Madrid, Europe

The findings bring the phenomenon — and the controversy — of the latest new and powerful weight loss drugs to the youngest age group yet. The new trial looked at liraglutide, the active ingredient used in two of Novo Nordisk’s older GLP-1 drugs: Saxenda, a weight loss drug, and Victoza, a diabetes drug. So instead of looking at overall weight loss like in adult studies, they decided to focus more on BMI, which takes into account both weight and height. A spokesperson for Novo Nordisk said that it has submitted an application to the Food and Drug Administration to expand the approval of liraglutide for weight loss in children ages 6 to 11. Is 6 too young for a weight loss drug?

Persons: Roy Kim, “, ” Kim, Claudia Fox, Fox, Eli Lilly, ”, liraglutide, ” Fox, Sarah Armstrong, ” Armstrong, comorbidities, it’s, ” Wegovy, Zepbound, Shauna Levy, ” Levy Organizations: New England, of Medicine, Novo Nordisk, Cleveland Clinic, Centers for Disease Control, University of Minnesota, BMI, Food and Drug Administration, American Academy of Pediatrics, Duke University, Tulane Bariatric Center Locations: liraglutide, Ozempic, Ohio, U.S, New Orleans

☆ Weight-loss drugs could stave off dementia, small study finds
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

Today, a group of dementia researchers from the UK released some early results that suggest it's possible these trendy injections might also stall the progression of dementia. A daily injection for brain preservationIuliia Burmistrova/Getty ImagesFor the study, researchers spent a year tracking brain changes across 204 Alzheimer's patients with mild to moderate disease. "It sounds like it is worth pursuing a larger trial, but these results cannot demonstrate that liraglutide can protect against dementia." Experts have seen how dementia patients' brains get worse and worse at efficiently using glucose for energy as their disease progresses, but the calculus is always complicated. Bigger studies using more powerful GLP-1 drugs for dementia are already ongoing.

Persons: Stephen Evans, Jason Kirk, Quynh Nguyen, hadn't, Dr, Paul Edison, it's, Edison, Alzheimer's Organizations: Service, Alzheimer's Association International Conference, London School of Hygiene, Medicine, Science Media, Nikon, Imperial College London, Food and Drug Administration, Novo Nordisk Locations: Philadelphia, Novo

☆ Scientists say weight-loss drugs could protect our brains from dementia. Early results suggest they're onto something.
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
▼ + stars: | 2024-07-30 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said. The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30. The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP. But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s. GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.

Persons: liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide Organizations: CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s Locations: United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish

☆ To help children with high BMI, expert panel recommends 26 hours of behavior coaching — but not weight-loss drugs
▼ + stars: | 2024-06-18 | by ( Jen Christensen | ) edition.cnn.com time to read: +9 min

The task force suggested that extensive and intensive behavioral interventions are the best way to help a child get to a healthy weight. A high BMI for a child is defined a little differently than it is for adults, although both use height and weight to estimate mass. Nearly 20% of children in the US have what’s considered a high BMI. The task force gives its guidelines letter grades based on the most up-to-date science. Under the Affordable Care Act, private insurers must cover preventive services that get a grade of A or B; the new child obesity recommendations got a B grade.

Persons: Susma Vaidya, ”, “, Dr, Mona Sharifi, ” Sharifi, Thomas Robinson, Sarah Armstrong, haven’t, Sharifi, Justin Ryder, Stanley Manne, Robert H, Lurie, “ I’ve, ” Ryder, Wegovy, Alli, Lomaira, John Ruiz, Sanjay Gupta, “ There’s, ” Vaidya, Vaidya, pharmacotherapy Organizations: CNN, US Preventive Services, Force, American Academy of Pediatrics, BMI, US Centers for Disease Control, Affordable, National Hospital, Yale School of Medicine, Stanford Solutions Science Lab, Department of Pediatrics, Pediatrics, Adolescent Health, Duke University Medical School, Stanley Manne Children’s, Ann, Lurie Children’s Hospital of Chicago, University of Arizona, CNN Health, FDA Locations: Washington

☆ People using popular drugs for weight loss, diabetes are more likely to be diagnosed with stomach paralysis, studies confirm
▼ + stars: | 2024-05-20 | by ( Brenda Goodman | ) edition.cnn.com time to read: +9 min

Injected medications called GLP-1 agonists are in high demand because they have proved to be so effective for weight loss. The difference, which was statistically significant, amounted to a 52% increased risk of being diagnosed with stomach paralysis while on a GLP-1 medication. Compared with those who were not taking a GLP-1 medication, those who did were about 66% more likely to be diagnosed with gastroparesis. This study found that 0.53% of patients on GLP-1 medications were diagnosed with stomach paralysis, or about 1 case of gastroparesis for every 200 people taking the drugs. People taking GLP-1 medications were also more likely to have nausea and vomiting or gastroesophageal reflux disease (GERD) and to be prescribed a proton pump inhibitor.

Persons: gastroparesis, GERD, ”, Prateek Sharma, Sharma, ” Sharma, Michael Camilleri, “, Camilleri, It’s, who’d, Dr, Sanjay Gupta, it’s Organizations: CNN, Drugmaker, Nordisk, University Hospitals, Diabetes, University of Kansas, University of Kansas School of Medicine, American Society, Mayo Clinic, CNN Health Locations: Washington, Cleveland, GLP, Mayo

☆ ‘Ozempic babies’: What the science says on whether GLP-1s lead to surprise pregnancies, and their safety if they do
▼ + stars: | 2024-05-08 | by ( Mira Cheng | Meg Tirrell | ) edition.cnn.com time to read: +12 min

“I was depressed, severely depressed for that whole time.”Five months earlier, in October 2022, Bentley had started taking Mounjaro for weight loss. Ozempic uses the active ingredient semaglutide, and Wegovy is the version approved for weight loss. Mounjaro uses tirzepatide, which also targets a second hormone called GIP, and Zepbound is its brand name for weight loss. Safety in pregnancyEven as GLP-1 medicines may increase fertility, little is known about their safety during pregnancy. “It’s kind of like heart failure or sleep apnea,” he said, referring to conditions for which GLP-1 drugs have recently shown positive results.

Persons: CNN — Catera Bentley, Bentley, ”, “, ” Bentley, she’d, —, ‘, ’ Bentley, Jody Dushay, Dushay, Catera Bentley, Ivy, Daniel Drucker, ” Drucker, they’re, Drucker, Eli Lilly, ” Dushay, haven’t, That’s, Anuja Dokras, Dokras, Melanie Cree, Cree, PCOS, aren’t, Eli Lilly’s, Daniel Skovronsky, ” Skovronsky, Dr, Sanjay Gupta, it’s, Mounjaro Organizations: CNN, Beth Israel Deaconess Medical Center, Harvard Medical School, University of, Mount Sinai, Novo Nordisk, Zepbound, US Centers for Disease Control, University of Pennsylvania, PCOS, Children’s Hospital, National Institutes of Health, CNN Health Locations: Steele , Alabama, Mount, United States, Children’s Hospital Colorado, —, Colorado

☆ EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
▼ + stars: | 2024-04-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator said Friday. The review examined several drugs from Novo Nordisk , including Wegovy and Ozempic. Clinical trials from Novo Nordisk and Eli Lilly have not demonstrated a link between GLP-1s and suicidal thoughts. The probe also included other active ingredients in older weight loss and diabetes drugs, including dulaglutide, exenatide and lixisenatide. Results from another study conducted by the agency also did not support a link between GLP-1 drugs and the risk of suicidal thoughts.

Persons: Eli Lilly, couldn't, Liraglutide Organizations: Novo Nordisk, European Union, European Medicines Agency, U.S . Food, Drug Administration, EMA, Icelandic Medicines Agency Locations: London, Britain, Novo, U.S, GLP, Wegovy, Ozempic

☆ What weight tells us about our health
▼ + stars: | 2024-01-17 | by ( Dr. Sanjay Gupta | ) edition.cnn.com time to read: +12 min

(CNN) — If you’ve been paying attention to health news recently, you may have noticed a subtle but real shift in the way society discusses body weight. Beyond health care dollarsDespite changing attitudes about larger bodies, excess weight does carry a price. From a health care standpoint, it costs the country a lot of money. According to a study published in the journal The Lancet in 2020, 27% of total health care expenditures in 2016 — about $730.4 billion — could be attributed to “modifiable risk factors” for preventable health conditions like cardiovascular disease. That was eight years ago, when our total health care expenditure was $2.7 trillion, according to the study.

Persons: you’ve, We’re, Dr, Fatima Cody Stanford, “, They’re, Adolphe Quetelet, Ancel Keys, ”, ” Stanford, Morgan, That’s, we’ll, Daniel Lieberman, who’ll, Oprah Organizations: CNN, American Medical Association, Massachusetts General Hospital, Harvard Medical School, National, bloodwork, Harvard Locations: Belgian

☆ Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +23 min

Novo spent at least $25.8 million over the past decade on U.S. medical professionals to promote its two obesity drugs, Wegovy and Saxenda, the analysis found. Jastreboff has also worked on clinical trials of obesity drugs for Eli Lilly, which markets a Wegovy competitor. Some doctors said Novo’s payments exemplify how the flood of industry money can dominate decision-making about care and coverage. Government pharmacy officer Solaru said her agency concluded that the new obesity drugs could be cost-effective by preventing other weight-related diseases and boosting workplace productivity. In January, the personnel office told its health plans they must cover at least one GLP-1 obesity drug for 8 million workers, retirees and family members.

Persons: Lee Kaplan, Kaplan, ”, gastroenterologist, He’s, Novo, Donna Ryan, Ryan, “, ” Kaplan, ” Novo, Robert Lustig, “ I’m, Lustig, They’re, Ania, ” Jastreboff, Jastreboff, Eli Lilly, Lilly’s Zepbound, Lilly, ” Lilly, Novo’s, Ayana, Sanders, Arthur Kellermann, ” Kellermann, mouthpieces, ’ ”, “ I'm, Jamy Ard, Ard, Dele, ” Solaru, ” Ryan, Scott Kahan, Kahan, Solaru, Christine Gallagher, Wegovy, Rebekah Carl, Carl, Jen Wexler, gaunt, Wexler Organizations: Novo Nordisk, Dartmouth, Nutrition Institute, Massachusetts General Hospital, Harvard Medical School, Reuters, Cambridge, Obesity Society, U.S ., Management, Reuters . Pharmaceutical, ”, U.S, United, National Health Service, University of California, U.S . Food, Drug Administration, Doctors, Wegovy’s, BMI, Yale University’s Center, Weight Management, Wall Street, American Medical Association, Rutgers University’s School of Public Health, Affordable, . Pharmaceutical, Companies, Uniformed Services University of Health Sciences, Wake Forest University, Wake Forest Baptist Health Weight Management, Obesity, Pennington Biomedical Research, U.S . National Institutes of Health, Personnel Management, Coalition, STOP, George Washington University, Novo Locations: CAMBRIDGE, Massachusetts, Boston, U.S, Novo, Danish, United States, Louisiana, San Francisco, Wegovy, Pennington, Baton Rouge , Louisiana, Government, New Columbia , Pennsylvania, Florida

Handout via REUTERS/File photo Acquire Licensing RightsSummaryCompanies Ozempic shortages expected throughout 2024Victoza shortages expected until at least Q2 2024Diabetes drug Ozempic used 'off label' to treat obesityNov 21 (Reuters) - Novo Nordisk (NOVOb.CO) will ration starter kits of Ozempic in Europe and reduce supplies of another diabetes drug, Victoza, to prioritise producing Ozempic, which has seen a surge in demand from people using it to lose weight. Ozempic contains semaglutide, an ingredient in Novo's hugely popular anti-obesity drug Wegovy. Intermittent Ozempic shortages are expected throughout 2024, while Victoza shortages are expected at least until the second quarter of 2024, according to the statement on the EMA's website. "No new patients should be started on Victoza until at least Q2 2024 when supply is expected to normalise," Novo urged doctors in the document. It also told doctors to consider other injectable GLP-1 drugs or "other suitable alternatives" where Ozempic or Victoza are not available for patients.

Persons: Ozempic, hasn't, Novo, Eli Lilly's, tirzepatide, Ludwig Burger, Eva Mathews, Emelia Sithole, Mark Potter Organizations: Handout, REUTERS, Diabetes, Novo Nordisk, European Medicines Agency, EU, Thomson Locations: Novo, London, Britain, Europe, Danish, United States, France, Austria, Belgium, Germany, Wegovy, Norway, Denmark, EU

☆ British health agency warns of fake Ozempic pens linked to hospitalizations
▼ + stars: | 2023-10-26 | by ( Amanda Musa | ) edition.cnn.com time to read: +3 min

CNN —Britain’s health agency is warning the public not to buy pre-filled pens claiming to contain the weight loss drugs Ozempic and Saxenda without a prescription, after a small number of people were hospitalized. Ozempic is used to treat adults with type 2 diabetes, and is used off-label for weight loss. More than 350 potentially fake Ozempic pens have been seized since January of this year, according to the MHRA. The agency has also received reports that patients have obtained fake Saxenda pens in the UK through “through non-legitimate routes.”No fake weight-loss pens were seized before January 2023, the agency says. The maker of both drugs, Novo Nordisk, told CNN Thursday that it is aware that counterfeit pens are being circulated.

Persons: Ozempic, ” Allison Schneider, Dr, Sanjay Gupta, Alison Cave, ” Ozempic, “, Meg Tirrell Organizations: CNN, Medicines, Healthcare, Agency, Novo Nordisk, “, “ Novo Nordisk, General Pharmaceutical Council, Get CNN, CNN Health, European Medicines Agency, European Union Locations: Ozempic, “ Novo, Novo, Germany, Europe

☆ Researchers link popular weight loss drugs to serious digestive problems for ‘hundreds of thousands’ worldwide
▼ + stars: | 2023-10-05 | by ( Brenda Goodman | ) edition.cnn.com time to read: +11 min

They can help people with diabetes control their blood sugar and lead to substantial weight loss for people with or without diabetes. Liraglutide was FDA approved as a weight loss medicine since 2014. What’s been less clear is whether patients taking these drugs for weight loss may have the same serious side effects. CNN reached out to Novo Nordisk, the manufacturer of both injectable weight loss drugs examined in this study, for comment. Sodhi said they started the man on a medication that treats stomach paralysis, “and he got a lot better,” Sodhi said.

Persons: Ozempic, ”, Mahyar, —, It’s, Liraglutide, it’s, Mohit Sodhi, Sodhi, Ian Musgrave, Musgrave, What’s, “, ” Sodhi, Dr, Sanjay Gupta Organizations: CNN, University of British, US Food and Drug Administration, FDA, “, University of Adelaide, Science Media Centre, BMI, Novo Nordisk, CNN Health Locations: University of British Columbia, Australia, Novo

☆ Weight loss drugs may be linked to stomach paralysis, other rare but severe issues, study says
▼ + stars: | 2023-10-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Blockbuster weight loss and diabetes drugs like Wegovy and Ozempic may be associated with an increased risk of three rare, but severe, stomach conditions in non-diabetic patients, according to a new epidemiological study released Thursday. Their research is the first large, population-level study to examine the risk of serious stomach conditions in non-diabetic patients specifically using GLP-1s for weight loss. People with diabetes are also at increased risk of experiencing stomach paralysis and pancreatitis overall, even without the treatments.

Persons: semaglutide, –, Mohit Sodhi Organizations: Blockbuster, JAMA, Novo Nordisk, University of British Columbia, Nordisk Locations: U.S

Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris (VTRS.O), to review the validity of the Wegovy and Ozempic patents. A spokesperson for Novo Nordisk said the company will "vigorously defend" its intellectual property. Novo has filed several U.S. patent lawsuits against companies including Pennsylvania-based Viatris that are seeking to market generic versions of the drugs. Viatris has separately asked a West Virginia federal court to invalidate the patents as part of the litigation.

Persons: Tom Little, Wegovy, Ozempic, Mylan, Viatris, Novo's Wegovy, Novo, Blake Brittain, Patrick Wingrove, Will Dunham, David Bario Organizations: Novo Nordisk, Danish, REUTERS, Rights, U.S . Patent, Mylan Pharmaceuticals, Viatris, West, Thomson Locations: Copenhagen, Denmark, Pennsylvania, West Virginia, Washington, New York

☆ Airlines might be quietly loving the Ozempic craze. The drugs could save United $80 million a year if each passenger dropped 10 pounds, one analyst estimated.
▼ + stars: | 2023-10-02 | by ( Kylie Kirschner | ) www.businessinsider.com time to read: +4 min

The rise in popularity of weight loss drugs like Ozempic and Wegovy could benefit airlines. One analyst estimated United would save $80 million a year if every passenger lost 10 pounds. AdvertisementAdvertisementUsing United Airlines as a model, Kahyaoglu estimated that if each passenger weighed 10 pounds less on average, the weight savings would equal around 1,790 pounds per flight. Insider reported in 2021 that the average weight of passengers had increased — American Airlines told Insider at the time that their average passenger was eight pounds heavier, at 182 pounds in summer and 187 pounds in winter. Both American and Southwest Airlines previously told Insider that they use data from the CDC to calculate passenger weight.

Persons: —, Sheila Kahyaoglu, liraglutide —, they've, Elon Musk, Boris Johnson, Amy Schumer, Charles Barkley, Sharon Osbourne Organizations: Service, Airlines, FAA, Jefferies, United Airlines, Southwest Airlines, CDC Locations: York City

☆ Airlines want you to lose weight. Ozempic could save them millions.
▼ + stars: | 2023-10-02 | by ( Kylie Kirschner | ) www.businessinsider.com time to read: +4 min

Airlines are consistently looking for ways to reduce plane weight to increase fuel efficiency. The rise in popularity of weight loss drugs like Ozempic and Wegovy could benefit airlines. AdvertisementAdvertisementThe recent boom of Ozempic, Wegovy, and other buzzy weight-loss drugs could do more than just help people lose weight — it could help the airline industry save money on fuel. Insider reported in 2021 that the average weight of passengers had increased — American Airlines told Insider at the time that their average passenger was eight pounds heavier, at 182 pounds in summer and 187 pounds in winter. Both American and Southwest Airlines previously told Insider that they use data from the CDC to calculate passenger weight.

Search resuls for: "Liraglutide"

25 mentions found